This study was approved on 04/30/2012 and is currently enrolling patients. Enrollment is currently 44% to completion. No safety and tolerability events have occurred to affect progression of the study. The study remains blinded, and therefore no additional detail or analysis will be available until after the completion of the dose escalation. Details of the study are posted at ClinicalTrial.gov http://clinicaltrials.gov/ct2/show/NCT01597401 and at the NIH Clinical Center web site: http://clinicalstudies.info.nih.gov/cgi/wais/bold032001.pl?A_12-H-0127.htmlaes-103

Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2012
Total Cost
$584,500
Indirect Cost
Name
National Heart, Lung, and Blood Institute
Department
Type
DUNS #
City
State
Country
Zip Code
Oder, Esther; Safo, Martin K; Abdulmalik, Osheiza et al. (2016) New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo? Br J Haematol 175:24-30
Safo, Martin K; Kato, Gregory J (2014) Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin. Hematol Oncol Clin North Am 28:217-31